Sarepta Therapeutics | SRPT - Equity Capital And Reserves



Sarepta Therapeutics reported $1.36B in Equity Capital and Reserves for its fiscal quarter ending in June of 2025.


Equity Capital And Reserves Change Date
Acadia Pharmaceuticals USD 822.38M 57.14M Jun/2025
Agios Pharmaceuticals USD 1.37B 96.97M Jun/2025
Alnylam Pharmaceuticals USD 250.59M 135.16M Jun/2025
Amgen USD 7.43B 1.22B Jun/2025
Biogen USD 17.63B 655.3M Jun/2025
BioMarin Pharmaceutical USD 6.03B 233.65M Jun/2025
Daiichi Sankyo JPY 1.58T 44.86B Jun/2025
Eli Lilly USD 18.27B 2.43B Jun/2025
Gilead Sciences USD 19.67B 596M Jun/2025
Incyte USD 4.17B 503.34M Jun/2025
Insmed USD 1.25B 1.15B Jun/2025
Ionis Pharmaceuticals USD 631.72M 156M Jun/2025
Moderna USD 9.4B 667M Jun/2025
Neurocrine Biosciences USD 2.69B 158.6M Jun/2025
Pfizer USD 88.7B 1.64B Jun/2025
PTC Therapeutics USD -206546000 20.79M Jun/2025
Regeneron Pharmaceuticals USD 29.94B 551.3M Jun/2025
Roche Holding CHF 36.16B 3.28B Dec/2024
Sanofi 70.28B 3.8B Jun/2025
Sarepta Therapeutics USD 1.36B 214.66M Jun/2025
Tectonic Therapeutic USD 283.77M 142.99M Jun/2025
Ultragenyx Pharmaceutical USD 151.29M 7.04M Jun/2025
Vertex Pharmaceuticals USD 17.18B 679.1M Jun/2025